secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001619856-24-000054
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou discontinues CAR-NK platform, cuts 12% workforce to extend cash runway into H2 2026
--------------------------------------------------------------------------------

- Preliminary cash $311.8M at June 30, 2024; expects to report Q2 results later.
- Discontinues allogeneic CAR-NK preclinical research; focuses on CAR-T cell therapy and four clinical programs.
- Workforce reduction of 21 positions (~12%); expects to complete by end of Q3 2024.
- Estimated severance costs $0.5M–$1.0M in Q3 2024.
- Cash runway extended at least 6 months into H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/0001619856-24-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer